Guardant Health ordered to pay $245M for DNA sequencing patent infringement
A US federal judge has ordered Guardant Health to pay over $245 million to TwinStrand Biosciences and the University of Washington. The ruling follows a jury verdict finding that Guardant Health had infringed patented DNA sequencing technology. Under the judgment, the company must pay an initial lump sum along with ongoing royalties through March 2033. Guardant Health has announced its intention to appeal the decision, expressing confidence in its legal position.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.
Discussion (0)
Log in to join the discussion and vote.
Log in